Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The NET-1 gene is a member of the newly discovered protein superfamily, especially in tumor tissues. The study found that NET-1 is closely related to tumor cell proliferation, adhesion, migration, invasion and induction of vascular formation, and has certain value for prognosis. The NET-1 gene and NET-2, NET-3, NET-4, NET-5, NET-6, and NET-7 are collectively referred to as NET-X and belong to one of the members of the tetrameric superfamily (TM4SF).
NET1 Features
Collectively known as net-x, net-1 and net-2 ~ 7 are members of seven new transmembrane 4 superfamily or tetraspan family (TM4SF) identified in the EST database in 2000 by Serru. Studies have shown that TM4SF acts as a molecular service protein to enhance functional signaling by linking specific cell surface proteins (such as lineage-specific proteins, integrins, other TM4SF molecules, etc.), which can transduce the formation and stability of complexes. Through this process, TM4SF is involved in cell activation and proliferation, adhesion and migration, differentiation and carcinogenesis.
Figure 1. An integrated model for the activation of canonical Wnt signaling by Net1. (Wei, S., et al. 2016)
Studies have shown that NET-1 mRNA is expressed in tumors such as cervical cancer, liver cancer, rectal cancer, gastric cancer and pancreatic cancer. At present, NET-1 is rarely reported in domestic and foreign literatures in lung cancer, esophageal cancer, and ovarian cancer. The study used RT-PCR to detect NET-1 and NET-7 genes in a variety of human cell lines. In addition, RT-PCR was used to screen 48 tissues and corresponding tumors in humans. It was found that NET-1 was expressed in almost all human tissues and corresponding tumors except for hematopoietic tissues and corresponding tumors, as well as the heart, brain and pancreas.
NET-1 and Tumor
RT-PCR was used to detect the expression of NET-1 gene in cervical cancer by mRNA level and immunohistochemical staining. The results showed that the NET-1 gene was expressed in CINIII and cervical squamous cell carcinoma, adenocarcinoma and cervical undifferentiated carcinoma. To investigate the expression of cyclooxygenase-2 (COX-2) and NET-1 gene in cervical cancer, it was found that NET-1 is not expressed in normal cervical tissues and is hardly expressed in CINI, but in CINII and CINIII. NET-1 positive cells gradually increase and spread throughout the epithelial layer. Similar to the reports of Wollscheid et al, the positive expression rates of NET-1 in CINIII and cervical cancer were 78.6% and 76.0%, respectively. The positive expression rate of CINIII was significantly higher than that of CINI and CINII, but before cervical cancer infiltration. There were no significant differences in the stages of cancer development. It suggests that the overexpression of NET-1 may be an early molecular event of cervical cancer, and NET-1 may be a tissue marker for early diagnosis of cervical cancer.
NET-1 protein is positively expressed in cytoplasm or membrane in hepatocellular carcinoma, and the positive rate is higher than that in adjacent tissues, suggesting that NET-1 as a membrane protein and cytoplasmic protein may transduce cell division signals and/or cause cell differentiation or dedifferentiation. Therefore, the function of liver cancer cells may be related to the accumulation of surface protein NET-1 in cancer cell populations. These proteins may synergistically produce tumor cell growth factors and promote tumor proliferation, suggesting that NET-1 gene may promote tumor formation, which may be a new marker in learning liver cancer tissue. 28 cases of paracancerous and non-cancerous liver tissue hepatocytes were pathologically characterized by varying degrees of hyperplasia, dysplasia or adenomatous hyperplasia, accompanied by cirrhosis or hepatitis background. Paracancerous cells may be transformed cells between normal cells and cancer cells, and NET-1 expression appears in this cell, suggesting that NET-1 expression may be an early event in liver cancer.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.